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P346 – Difference in mean VAS reduction (Nimesulide ER - Diclofenac SR), with 95% CI
Product Nimesulide ER Diclofenac SR NIM - DIC 95% CI
N N LL UL
Mean VAS reduction 131 5.46 131 4.87 0.59 -0.091 1.284
and day 30. WOMAC OA index 3.1 was evaluated at enrollment
and end of therapy. Nimesulide ER was to be considered non-
inferior if the lower bound of 95% confidence interval (CI) for the
treatment difference (Test - Reference) in mean VAS reduction
for pain was less than 1 cm (clinically acceptable significant dif-
ference). Safety was evaluated by analyzing all reported clinical
and laboratory adverse events.
Results: In mITT analysis mean VAS reduction was 5.46 for
Nimesulide ER and 4.87 for Diclofenac SR. The treatment differ-
ence (Nimesulide ER - Diclofenac SR) in mean VAS reduction
was 0.59, with a lower bound 95% CI of -0.091, which was within
the pre-specified non-inferiority margin of 1 cm.
In both treatment arms statistically significant decrease in pain
was observed from baseline to 30 min after treatment, with
additional decrease occurring at subsequent hours on Day 1 and
during observations made on Day 15 and Day 30. On Day 1,
maximum pain relief was achieved after 12 h in both arms (45%
and 41% reduction from baseline for Willgo and Voveran SR,
respectively). The VAS scores obtained in the Willgo treatment
group were lower than that in the Voveran SR treatment group
at every assessment. Statistically significant lower scores were
observed at 8 h (Day 1) and Day 30 for Willgo group as compared
to the Voveran SR group (p<0.05).
No statistically significant difference was observed in the
WOMAC scores obtained in the two groups at baseline (66.57
for Willgo and 65.58 for Voveran SR). Both groups exhibited a
statistically significant decrease in WOMAC scores at the end of
the therapy. The Willgo group had a favorable reduction (56.1%)
compared with that of Voveran SR (50.3%). Both the study treat-
ment produced significant improvement in global assessment of
efficacy and tolerability as assessed by the investigators and the
patients.
Both treatments were well tolerated and the reported adverse
events were mild and transient in nature. No SAE was reported
in either treatment.
Conclusions: Based on the study results, it can be concluded
that Willgo® is non-inferior to Voveran SR® with regard to mean
VAS reduction of patient self assessed pain and has a compara-
ble tolerability profile to that of Voveran SR®.
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Purpose: Background: Symptoms are transcient and unpre-
dictable in HOA. In particular, we miss data on patients affected
by a recent exacerbation of their symptoms ("flare").
Aim of this study: To describe and compare the characteris-
tics of hand OA patients whose symptoms are flaring versus
"quiescent" HOA.
Methods: Prospective cross-sectional clinical study. A sample of
100 French rheumatologists and 100 general practitioners (GPs)
had to describe 2 HOA patients presenting consecutively: 1 with
a flare of symptoms, i.e. pain score ≥ 50 mm on a VAS and
functional index for hand OA score (FIHOA) ≥ 5, and 1 with
quiescent symptoms (pain < 50 mm and FIHOA < 5). Patients
were both gender, age ≥ 45 years, fulfilling the ACR criteria, and
were initially separated according to the level of symptoms. Data
collected: Doctors characteristics, patients demographic data and
HOA description. Statistics: descriptive: numbers (%) and mean
(SD).
Results: 169 doctors (aged 50 years, 69% men) described 316
patients of which 178 (56%) were in the "flare" and 44% in the
non-flare group. 83% were women, aged 66 (10) years, with a
BMI of 25 (4), 29% still professionally active. 60% had a familial
history of HOA (mother affected mostly), 95% of women were
menopaused (mean age (51). There was no difference between
the two groups with respect to these data. Conversely patients
in the flare group were more often affected by OA in another site
(84% vs 71%; p < 0.01, mostly knee OA [75%]). Thumb base OA
was more frequent in the flare group (82% vs 68%; p= 0.004).
Symptoms were more recent (mean duration since 1st symptom:
1(4) vs 5 (5) years. There was no difference regarding the %
of right vs left-handed, the overall prevalence (80% vs 77%)
of Heberden/Bouchard nodes, or their site prevalence (75%
Heberden, 52% Bouchard) and number (6 (4) in both groups).
FIHOA score averaged 12 (4) in the flare group vs 4 (1). All the
items of the FIHOA showed differences between the 2 groups.
Pain score rated 66 (9) mm in the "flare" group vs 30 (11) mm in
the non-flare group.
Conclusions: There are some differences between HOA pa-
tients whose symptoms flare and patients with a quiescent OA: a
shorter duration since 1st symptom, thumb base more frequently
affected, and a higher prevalence of OA at another site (knee).
A cut-off of 50 mm on a pain VAS could allow to select "flaring"
patients in clinical studies.
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Purpose: Many individuals diagnosed with knee osteoarthritis
(OA) develop functional gait limitations, especially reduced walk-
ing speeds and limited knee motion during limb advancement.
The benefits of celecoxib in reducing joint inflammation and
symptoms associated with knee OA have been well described.
However, little is known about the effects of pain and stiffness re-
duction on walking function. The aim of this study was to measure
with clinically available tools common gait parameters, functional
walking performance, as well as perceived pain, stiffness, and
function before and during a short course of celecoxib.
Methods: Eight subjects with symptomatic knee OA, 2 males and
6 females, with a mean age of 59 years (range 46-70) completed
testing procedures at a physicians’ office in a large University
Medical School setting. Each subject attended a screening visit
where the diagnosis of knee OA was confirmed and VAS scores
after a 50 feet walk test were recorded. If a subject was on
regular doses of analgesic medication, VAS range was required
to be between 30 mm and 90 mm. If not on regular doses of
